{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T09:19:55Z","timestamp":1791623995027,"version":"4.3.4"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T00:00:00Z","timestamp":1691020800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81201682"],"award-info":[{"award-number":["81201682"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.lungcan.2023.107319","type":"journal-article","created":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T01:48:02Z","timestamp":1691372882000},"page":"107319","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Comparative safety of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced anaplastic lymphoma kinase-mutated non-small cell lung cancer: Systematic review and network meta-analysis"],"prefix":"10.1016","volume":"184","author":[{"given":"Yuyao","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XuanZhu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guotao","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8133-4082","authenticated-orcid":false,"given":"Sheng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2021","key":"10.1016\/j.lungcan.2023.107319_b0005","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2020","journal-title":"CA Cancer J. Clin."},{"issue":"Suppl 4","key":"10.1016\/j.lungcan.2023.107319_b0010","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"ESMO Guidelines Committee, Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2023.107319_b0015","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2023.107319_b0020","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1097\/JTO.0b013e3181c4dedb","article-title":"ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer","volume":"4","author":"Solomon","year":"2009","journal-title":"J. Thoracic Oncol."},{"key":"10.1016\/j.lungcan.2023.107319_b0025","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ctrv.2013.07.002","article-title":"ALK inhibitors in the treatment of advanced NSCLC","volume":"40","author":"Gridelli","year":"2014","journal-title":"Cancer Treat. Rev."},{"issue":"Suppl 2","key":"10.1016\/j.lungcan.2023.107319_b0030","doi-asserted-by":"crossref","first-page":"e000524","DOI":"10.1136\/esmoopen-2019-000524","article-title":"How I treat ALK-positive non-small cell lung cancer","volume":"4","author":"McCusker","year":"2019","journal-title":"ESMO Open."},{"key":"10.1016\/j.lungcan.2023.107319_b0035","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1158\/2159-8290.CD-16-1123","article-title":"Targeting ALK: precision medicine takes on drug resistance","volume":"7","author":"Lin","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.lungcan.2023.107319_b0040","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1158\/1078-0432.CCR-11-2906","article-title":"Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer","volume":"18","author":"Doebele","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2023.107319_b0045","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nrc.2017.84","article-title":"Understanding and targeting resistance mechanisms in NSCLC","volume":"17","author":"Rotow","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.lungcan.2023.107319_b0050","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"issue":"may14 2","key":"10.1016\/j.lungcan.2023.107319_b0055","doi-asserted-by":"crossref","first-page":"f2914","DOI":"10.1136\/bmj.f2914","article-title":"Demystifying trial networks and network meta-analysis","volume":"346","author":"Mills","year":"2013","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.lungcan.2023.107319_b0060","doi-asserted-by":"crossref","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in Stata","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.lungcan.2023.107319_b0065","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/1536867X0900900103","article-title":"Multivariate random-effects meta-analysis","volume":"9","author":"White","year":"2009","journal-title":"Stata J."},{"key":"10.1016\/j.lungcan.2023.107319_b0070","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/1536867X1101100206","article-title":"Multivariate random-effects meta-regression: updates to Mvmeta","volume":"11","author":"White","year":"2011","journal-title":"Stata J."},{"key":"10.1016\/j.lungcan.2023.107319_b0075","doi-asserted-by":"crossref","first-page":"e2017047","DOI":"10.4178\/epih.e2017047","article-title":"Network meta-analysis: application and practice using Stata","volume":"39","author":"Shim","year":"2017","journal-title":"Epidemiol. Health."},{"key":"10.1016\/j.lungcan.2023.107319_b0080","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.lungcan.2023.107319_b0085","doi-asserted-by":"crossref","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","article-title":"Conceptual and technical challenges in network meta-analysis","volume":"159","author":"Cipriani","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.lungcan.2023.107319_b0090","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Res. Synth. Methods"},{"key":"10.1016\/j.lungcan.2023.107319_b0095","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat. Med."},{"key":"10.1016\/j.lungcan.2023.107319_b0100","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/jep.13159","article-title":"Comparison of four heterogeneity measures for meta-analysis","volume":"26","author":"Lin","year":"2020","journal-title":"J. Eval. Clin. Pract."},{"key":"10.1016\/j.lungcan.2023.107319_b0105","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"CROWN trial investigators, first-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2023.107319_b0110","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"PROFILE 1014 investigators, first-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2023.107319_b0115","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"ALEX trial investigators, Alectinib versus crizotinib in Untreated ALK-Positive non-small-Cell Lung Cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2023.107319_b0120","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","article-title":"Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial","volume":"390","author":"Hida","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2023.107319_b0125","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2023.107319_b0130","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jamaoncol.2021.3523","article-title":"Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer: A randomized clinical trial","volume":"7","author":"Horn","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lungcan.2023.107319_b0135","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S2213-2600(19)30053-0","article-title":"Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study","volume":"7","author":"Zhou","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.lungcan.2023.107319_b0140","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-Positive non-small-Cell Lung Cancer, N","volume":"379","author":"Camidge","year":"2018","journal-title":"Engl. J. Med."},{"key":"10.1016\/j.lungcan.2023.107319_b0145","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.jtho.2018.06.012","article-title":"Results of PROFILE 1029, a Phase III Comparison of first-Line crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced non-small Cell Lung Cancer","volume":"13","author":"Wu","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2023.107319_b0150","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/annonc\/mdy121","article-title":"Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study","volume":"29","author":"Novello","year":"2018","journal-title":"Ann. Oncol."},{"issue":"10072","key":"10.1016\/j.lungcan.2023.107319_b0155","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","volume":"389","author":"Soria","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2023.107319_b0160","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S1470-2045(17)30339-X","article-title":"Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2023.107319_b0165","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1200\/JCO.2016.71.5904","article-title":"Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial","volume":"35","author":"Kim","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2023.107319_b0170","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/pds.1211","article-title":"Hy\u2019s law: predicting serious hepatotoxicity","volume":"15","author":"Temple","year":"2006","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.lungcan.2023.107319_b0175","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1470-2045(15)00488-X","article-title":"study investigators, Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial","volume":"17","author":"Shaw","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2023.107319_b0180","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1200\/JCO.2015.63.9443","article-title":"Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: A Phase II global study","volume":"34","author":"Ou","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2023.107319_b0185","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1200\/JCO.2016.71.3701","article-title":"Open-label, multicenter, Phase II study of ceritinib in patients with non-small-cell lung cancer harboring ROS1 rearrangement","volume":"35","author":"Lim","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2023.107319_b0190","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1158\/1078-0432.CCR-17-2398","article-title":"Ensartinib (X-396) in ALK-positive non-small cell lung cancer: results from a first-in-human Phase I\/II, multicenter study","volume":"24","author":"Horn","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2023.107319_b0195","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(19)30252-8","article-title":"Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial","volume":"8","author":"Yang","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.lungcan.2023.107319_b0200","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(17)30680-0","article-title":"Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2023.107319_b0205","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","article-title":"Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study","volume":"19","author":"Solomon","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2023.107319_b0210","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1007\/s12325-020-01365-3","article-title":"Consensus recommendations for management and counseling of adverse events associated with lorlatinib: A guide for healthcare practitioners","volume":"37","author":"Reed","year":"2020","journal-title":"Adv. Ther."},{"key":"10.1016\/j.lungcan.2023.107319_b0215","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1634\/theoncologist.2018-0380","article-title":"Clinical management of adverse events associated with lorlatinib","volume":"24","author":"Bauer","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.lungcan.2023.107319_b0220","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1021\/jm500261q","volume":"57","author":"Johnson","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.lungcan.2023.107319_b0225","first-page":"CD013453","article-title":"Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer","volume":"1","author":"Cameron","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.lungcan.2023.107319_b0230","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.lungcan.2020.04.011","article-title":"Efficacy and safety of ALK inhibitors in ALK-rearranged non-small cell lung cancer: A systematic review and meta-analysis","volume":"144","author":"Breadner","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2023.107319_b0235","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.lungcan.2021.08.014","article-title":"ALK inhibitor-induced bradycardia: A systematic-review and meta-analysis","volume":"161","author":"Cirne","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2023.107319_b0240","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.2217\/fon-2018-0608","article-title":"Ocular and orbital side effects of ALK inhibitors: a review article","volume":"15","author":"Chelala","year":"2019","journal-title":"Future Oncol."},{"key":"10.1016\/j.lungcan.2023.107319_b0245","doi-asserted-by":"crossref","first-page":"e13726","DOI":"10.1097\/MD.0000000000013726","article-title":"Meta-analysis of overall incidence and risk of ALK inhibitors-induced liver toxicities in advanced non-small-cell lung cancer","volume":"98","author":"Li","year":"2019","journal-title":"Med. (Baltim.)"},{"key":"10.1016\/j.lungcan.2023.107319_b0250","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.lungcan.2019.04.015","article-title":"The incidence of ALK inhibitor-related pneumonitis in advanced non-small-cell lung cancer patients: A systematic review and meta-analysis","volume":"132","author":"Suh","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2023.107319_b0255","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jtho.2019.10.006","article-title":"Ceritinib plus nivolumab in patients with advanced ALK-rearranged non-small cell lung cancer: results of an open-label, multicenter, phase 1B study","volume":"15","author":"Felip","year":"2020","journal-title":"J. Thorac. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223008577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223008577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:06:19Z","timestamp":1777518379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500223008577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":51,"alternative-id":["S0169500223008577"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107319","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative safety of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced anaplastic lymphoma kinase-mutated non-small cell lung cancer: Systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107319","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107319"}}